Scribe Therapeutics posts second-quarter revenue of $1.92 million, EPS $(2.62)
Scribe Therapeutics reported second-quarter 2026 revenue of $1.92 million and a net loss attributable to common stockholders of $6.48 million, or diluted loss per share of $(2.62).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.